📚 Part of the GLP-1 Receptor Agonists Trial Guide — every landmark trial in one place.
Series: Landmark Trials in Endocrinology & Metabolism | Study #8
Category: GLP-1 Receptor Agonists · Cardiovascular Outcomes | Design: Multicentre, double-blind, placebo-controlled RCT | n: 9,340 | Follow-up: 3.8 years (median)
📋 Summary
Authors: Marso SP et al., for the LEADER Trial Investigators
Journal: N Engl J Med 2016;375:311–322 | DOI: 10.1056/NEJMoa1603827
LEADER enrolled 9,340 patients with type 2 diabetes mellitus and either established cardiovascular disease or age 60 years or older with cardiovascular risk factors. Patients were randomly assigned to liraglutide 1.8 mg once daily by subcutaneous injection or placebo, added to standard care. The primary composite outcome was the first occurrence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke (3-point MACE). Over a median follow-up of 3.8 years, the primary outcome occurred in 13.0% of patients in the liraglutide group and 14.9% in the placebo group (HR 0.87; 95% CI 0.78 to 0.97; p<0.001 for noninferiority, p=0.01 for superiority). Cardiovascular death was the component most strongly reduced (HR 0.78; 95% CI 0.66 to 0.93), representing a 22% reduction. All-cause mortality was also significantly reduced (HR 0.85; 95% CI 0.74 to 0.97). Nonfatal myocardial infarction showed a non-significant trend towards reduction (HR 0.88; 95% CI 0.75 to 1.03), and nonfatal stroke was not reduced (HR 1.11; 95% CI 0.88 to 1.39). Hospitalisation for heart failure was not significantly affected (HR 0.87; 95% CI 0.73 to 1.05). LEADER was the first cardiovascular outcomes trial of a GLP-1 receptor agonist to demonstrate superiority over placebo, establishing liraglutide as the first drug in this class with a positive cardiovascular outcomes trial.
📊 Key Findings
| Outcome | Liraglutide | Placebo | Effect Size |
|---|---|---|---|
| 3-point MACE (CV death, MI, stroke) | 13.0% | 14.9% | HR 0.87 (0.78–0.97) · p=0.01 (superiority) |
| Cardiovascular death | — | — | HR 0.78 (0.66–0.93) · 22% RRR |
| All-cause mortality | — | — | HR 0.85 (0.74–0.97) |
| Nonfatal MI | — | — | HR 0.88 (0.75–1.03) · NS |
| Nonfatal stroke | — | — | HR 1.11 (0.88–1.39) · NS |
| HF hospitalisation | — | — | HR 0.87 (0.73–1.05) · NS |
| Absolute risk reduction (MACE) | ~1.9% over 3.8 years | NNT approximately 53 | |
LEADER — Liraglutide and cardiovascular outcomes
Cardiovascular outcomes trial · type 2 diabetes, high CV risk · 3.8 years
First GLP-1 receptor agonist CVOT to show superiority. The benefit is driven by cardiovascular death, an atherosclerotic profile distinct from SGLT2 inhibitors. Absolute effect is modest (NNT around 53).
💬 Expert Commentary
LEADER established liraglutide as the first GLP-1 receptor agonist with a positive cardiovascular outcomes trial and defined the mechanistic profile of cardiovascular protection with this drug class. The component analysis reveals a pattern that became the hallmark of GLP-1 receptor agonist CVOTs: the cardiovascular benefit is driven predominantly by a reduction in cardiovascular death and, in subsequent trials, nonfatal stroke, rather than nonfatal MI, and notably does not extend to heart failure hospitalisation. This pattern contrasts with the SGLT2 inhibitors, whose cardiovascular protection is driven primarily by heart failure and renal endpoints. The mechanistic interpretation points to an anti-atherosclerotic pathway for GLP-1 receptor agonists, potentially mediated through improvements in endothelial function, reduced systemic inflammation, modest reductions in blood pressure and body weight, and direct cardiac and vascular effects of GLP-1 receptor signalling, rather than the haemodynamic and tubular mechanisms that dominate the SGLT2 inhibitor story.
The 22% reduction in cardiovascular death in LEADER, in a trial population with predominantly established cardiovascular disease, is among the most clinically meaningful individual endpoint reductions reported in any diabetes CVOT. The NNT of approximately 53 over 3.8 years reflects the background event rate in a high-risk but not extreme-risk population, and the absolute benefit would be expected to be larger in populations with more severe or recent cardiovascular disease. LEADER also established that liraglutide has a favourable cardiorenal safety profile, with no excess in heart failure hospitalisation, diabetic ketoacidosis, or limb amputation. The absence of a stroke reduction, and the numerical elevation in nonfatal stroke (HR 1.11), was not replicated across subsequent GLP-1 receptor agonist CVOTs and is considered a chance finding rather than a drug-specific signal. Subsequent meta-analyses across the class demonstrate a consistent stroke reduction, most pronounced in SUSTAIN-6 and REWIND.
Limitations: The absolute risk reduction of 1.9% corresponds to a NNT of 53, which is modest compared with the HFrEF and nephropathy trials in this series. Heart failure hospitalisation was not reduced, distinguishing liraglutide from SGLT2 inhibitors in terms of cardiorenal mechanism. The benefit was driven predominantly by cardiovascular death, and MI and stroke individually did not reach significance. The study was industry-sponsored by Novo Nordisk.
🔑 BOTTOM LINE
LEADER demonstrated that liraglutide reduces 3-point MACE and cardiovascular death in patients with type 2 diabetes and high cardiovascular risk, establishing GLP-1 receptor agonists as the second drug class after SGLT2 inhibitors with proven cardiovascular benefit in diabetes, and characterising an atherosclerotic rather than a heart failure protection profile for this class.
⭐ Clinical Impact Rating: ●●●●● Practice-defining